Survival Curve from Scientific Research

Patients with PD-L1 expression level of 1 ≤ CPS < 10. For serplulimab + CF, n = 206, median OS 14.2 months (95% CI, 11.5–15.3 months). For placebo + CF, n = 104, median OS 11.4 months (95% CI, 9.2–14.0 months). HR, 0.74; 95% CI, 0.54–1.03; P = 0.066.

DOI